Arovella Therapeutics Ltd (ASX:ALA) managing director and CEO Dr Michael Baker walks Proactive’s Elisha Newell through the company’s renewed focus on iNKT cell therapy and its implications for the oncology space. The biotech recently presented data at the American Association for Cancer Research’s annual conference and spent the last six months recruiting talent to support its clinical vision. Baker says the company’s strategy has ‘significant’ potential to generate allogeneic cell therapies that target both blood cancers and solid tumours.
Arovella Therapeutics progresses patient-focused iNKT vision
